Welcome to our dedicated page for Alumis news (Ticker: ALMS), a resource for investors and traders seeking the latest updates and insights on Alumis stock.
About Alumis Inc.
Alumis Inc. (Nasdaq: ALMS) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment landscape for immune-mediated diseases through precision medicine. Headquartered in South San Francisco, California, the company leverages its proprietary precision data analytics platform to identify, develop, and commercialize innovative therapies targeting autoimmune and inflammatory disorders. Alumis aims to replace the traditional broad-spectrum immunosuppression approach with safer, more effective targeted therapies, improving patient outcomes and quality of life.
Pipeline and Key Products
At the core of Alumis’ pipeline is ESK-001, a next-generation, highly selective oral TYK2 inhibitor. ESK-001 is designed to correct immune dysregulation by targeting pro-inflammatory mediators such as IL-23, IL-17, and type 1 interferon, while minimizing off-target effects. It is currently undergoing Phase 3 clinical trials for moderate-to-severe plaque psoriasis and Phase 2 trials for systemic lupus erythematosus (SLE). The compound has demonstrated promising efficacy and safety profiles in earlier trials, showing dose-dependent improvements in clinical outcomes.
Another key asset is A-005, a CNS-penetrant TYK2 inhibitor. This first-in-class therapy is being developed for neuroinflammatory and neurodegenerative diseases, including multiple sclerosis. A-005’s ability to cross the blood-brain barrier and achieve maximal TYK2 inhibition positions it as a potential breakthrough treatment for central nervous system disorders.
Precision Data Analytics Platform
Alumis’ proprietary precision data analytics platform underpins its drug discovery and development efforts. By integrating genetic, translational, and clinical insights, the platform enables the identification of optimal therapeutic targets and pathways. This precision approach not only accelerates development timelines but also enhances the likelihood of clinical and regulatory success, setting Alumis apart in the competitive biopharmaceutical landscape.
Market Context and Competitive Position
Alumis operates in the rapidly growing field of autoimmune and inflammatory disease therapeutics, a market driven by the increasing prevalence of chronic conditions and the demand for safer, more effective treatments. The company faces competition from established players such as Bristol-Myers Squibb, but its focus on precision medicine and its differentiated TYK2 inhibitors provide a competitive edge. Alumis’ strategy to develop both systemic and CNS-targeted therapies further broadens its market potential.
Vision and Leadership
Founded with a mission to redefine the standard of care for immune-mediated diseases, Alumis is led by a team of industry veterans with deep expertise in drug discovery, immunology, and clinical development. The company’s leadership is committed to advancing its pipeline with scientific rigor and operational excellence, aiming to bring transformative therapies to patients worldwide.
Conclusion
Alumis Inc. represents a compelling investment opportunity in the biopharmaceutical sector, with its innovative approach to precision medicine, a robust clinical pipeline, and a focus on addressing unmet needs in autoimmune and inflammatory diseases. By leveraging cutting-edge analytics and a patient-centric approach, the company is well-positioned to deliver long-term value to stakeholders while transforming lives through groundbreaking therapies.
Alumis (NASDAQ: ALMS) and ACELYRIN (NASDAQ: SLRN) have reaffirmed their commitment to merge in an all-stock transaction, creating a leading clinical-stage biopharma company focused on immune-mediated diseases. The merger is expected to close in Q2 2025.
The combined entity will have a pro forma cash position of approximately $737 million as of December 31, 2024, providing runway into 2027. The portfolio includes late-stage clinical assets targeting multi-billion dollar markets, including ESK-001 for psoriasis and lupus, lonigutamab for thyroid eye disease, and A-005 for multiple sclerosis.
Key benefits include:
- Enhanced financial flexibility to advance late-stage pipeline
- Combined cash position from Alumis ($289M) and ACELYRIN ($448M)
- Multiple planned key data readouts across clinical trials
- Experienced leadership team with track record of value creation
Alumis (NASDAQ: ALMS) has announced multiple presentations of its Phase 2 open-label extension (OLE) study data for ESK-001, their oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis, at the 2025 American Academy of Dermatology (AAD) annual meeting in Orlando.
The presentations include a late-breaking oral presentation highlighting 52-week data and three e-posters covering patient-reported outcomes, disease biomarker activity, and pharmacokinetic data. The company will present findings on March 8, 2025, with additional e-poster presentations focusing on Asian population comparisons and biomarker modulation.
Notably, Alumis has accelerated its timeline for the Phase 3 ONWARD clinical program topline data readout, now expected in Q1 2026, citing strong patient and investigator interest in the program.
Alumis (Nasdaq: ALMS) announced new Phase 1 data presentations for A-005, their first-in-class CNS penetrant TYK2 inhibitor, at the ACTRIMS Forum 2025. A-005 demonstrated potent inhibition of TYK2-specific signaling in immune cells and CNS resident cells, with the ability to cross the blood-brain barrier.
The Phase 1 clinical trials showed that A-005 was well-tolerated and achieved maximal TYK2 inhibition across various doses. The company plans to advance to Phase 2 clinical trials for multiple sclerosis patients in the second half of 2025.
Two presentations are scheduled for February 28, 2025: one focusing on A-005's effects on astrocytes and microglia (Poster P352), and another discussing safety, tolerability, and pharmacokinetics in healthy volunteers (Poster P335).
Alumis (Nasdaq: ALMS), a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. Martin Babler, the company's President and CEO, will deliver a presentation at the virtual event on Tuesday, February 11, 2025, at 3:20 pm ET. Interested parties can access a live webcast of the presentation through the 'Events' page in the 'Investors' section of the Alumis website.
Alumis (ALMS) and ACELYRIN (SLRN) announced a merger agreement creating a late-stage clinical biopharma company focused on immune-mediated diseases. The all-stock transaction will result in Alumis stockholders owning ~55% and ACELYRIN stockholders ~45% of the combined company.
The merged entity will operate under the Alumis name with a pro forma cash position of approximately $737 million as of December 31, 2024, providing runway into 2027. The combined pipeline includes Alumis' ESK-001, currently in Phase 3 trials for psoriasis with topline data expected in H1 2026, and ACELYRIN's lonigutamab for thyroid eye disease.
The transaction is expected to close in Q2 2025, subject to stockholder approval. Stockholders representing ~62% of Alumis and ~24% of ACELYRIN have already agreed to support the merger.
Alumis (Nasdaq: ALMS) has strengthened its leadership team with key appointments to support its transition to a late-stage company. Jack Danilkowicz has been appointed as Chief Commercial Officer, bringing extensive experience in commercial strategies from Amgen and Horizon Therapeutics, where he helped grow annual net product sales from $300 million to nearly $4 billion.
Sara Klein has been promoted to Chief Legal Officer, continuing to direct corporate legal and compliance matters. Roy Hardiman, the previous legal officer, will now serve as Chief Business and Strategy Officer. These appointments come as Alumis advances its next-generation TYK2 inhibitor ESK-001 through Phase 3 ONWARD clinical program in plaque psoriasis and a potential pivotal Phase 2b trial in systemic lupus erythematosus.
Alumis (NASDAQ: ALMS) announced positive Phase 1 clinical trial results for A-005, their CNS penetrant TYK2 inhibitor. The trial demonstrated that A-005 successfully crosses the blood-brain barrier and achieves maximal TYK2 inhibition with favorable pharmacokinetics in both CNS and peripheral systems.
Key findings include: no serious adverse events reported, significant and prolonged exposure in cerebral spinal fluid, dose-proportional drug exposure, peak drug concentration with half-lives up to 12 hours, and established PK/PD relationship showing sustained TYK2 inhibition. The company plans to advance to Phase 2 clinical trials for multiple sclerosis in the second half of 2025.
Alumis (Nasdaq: ALMS) announced two data presentations at ACR Convergence 2024 highlighting their oral treatment ESK-001 for Systemic Lupus Erythematosus (SLE). The presentations demonstrate that ESK-001, a selective allosteric oral tyrosine kinase 2 (TYK2) inhibitor, effectively suppresses both a novel disease biomarker and Type 1 interferons, which are key drivers of SLE. The company's proprietary data analytics platform identified novel pathways in SLE that can be suppressed through TYK2 inhibition. The Phase 2b LUMUS study in SLE is ongoing, with top-line data expected in 2026.
Alumis (NASDAQ: ALMS) reported Q3 2024 financial results and recent achievements. The company presented promising data at EADV for ESK-001 in psoriasis treatment, with 93% of patients achieving PASI 75 at the 40mg twice daily dose. Currently advancing three clinical programs: Phase 3 ONWARD trials for psoriasis, Phase 2b for systemic lupus erythematosus, and Phase 1 for A-005 in neuroinflammatory diseases. Q3 financial results showed cash position of $361.9 million, expected to fund operations into 2026. Net loss increased to $93.1 million compared to $43.4 million in Q3 2023, with R&D expenses at $87.8 million and G&A expenses at $10.6 million.
Alumis (Nasdaq: ALMS) has announced its participation in Guggenheim's Inaugural Healthcare Innovation Conference. President and CEO Martin Babler will engage in a fireside chat on Tuesday, November 12, 2024, at 2:00 pm ET in Boston, MA. The clinical-stage biopharmaceutical company, which focuses on developing oral therapies for immune-mediated diseases using precision approaches, will provide a live webcast of the event on their website's Investors section. The webcast recording will remain accessible for 90 days after the event.
FAQ
What is the current stock price of Alumis (ALMS)?
What is the market cap of Alumis (ALMS)?
What does Alumis Inc. specialize in?
What is ESK-001?
What makes Alumis’ approach unique?
What diseases does Alumis target?
How does Alumis differentiate from competitors?
What is A-005?
What stage are Alumis’ clinical trials in?
What is TYK2 inhibition?
